BioWorld Asia

May 27, 2009

Santhera's Stock Plummets on Idebenone Phase III Miss

Shares in Santhera Pharmaceuticals Holding AG plunged 40 percent last week on news that its lead compound Catena (idebenone) missed the primary endpoint in a U.S. Phase III trial in patients with Friedreich's Ataxia. (BioWorld International) Read More

Sanofi, Roche Outline Partnering Strategies

RNA Toolbox Could Help Deliver Cancer Therapies

Institute for Deaf Calls for More Biotech Work in Hearing Loss

IVT, FIT Biotech Team Up on DNA-based HIV Vaccine

West Faces Brain Drain as India, China Natives Return

Clarity, Due Diligence Vital in Cross-Border Alliances

Stem Cell Companies Report Some Progress, Much Hype

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...